METHOTREXATE, VIALS 1 Indications

methotrexate, vials

(

Methotrexate Injection USP is indicated for Neoplastic diseases: 

  • Choriocarcinoma: Methotrexate - as single chemotherapy or in combination with other drugs.
  • Intermediate, or high-grade Non-Hodgkin's Lymphoma - as part of ProMACE-CytaBOM, ProMACE-MOPP, and Magrath protocols.
  • Breast Cancer - as part of CMF (cyclophosphamide-methotrexate-fluorouracil) therapy.
  • Acute Lymphoblastic Leukemia - as maintenance therapy.
  • Head and Neck Cancer - in combination with other chemotherapies.
  • Gastric Cancer - palliative combination chemotherapy.
  • Metastasis of unknown primary - as palliative combination chemotherapy.
  • Osteogenic sarcoma (adjuvant) - high dose methotrexate with leucovorin rescue (HDMTX-LV)
  • Bladder Cancer (advanced) - as part of the M-VAC Regimen.
  • Leptomeningeal spread of malignancies (carcinomatosis/leukemia/lymphoma) as a single chemotherapy or alternating with Ara-C
  • Burkitt's lymphoma.
  • Advanced stages of childhood lymphoma (III and IV, St. Jude's Childrens' Research Hospital Staging System).
  • Advanced cases of mycosis fungoides (cutaneous T-cell lymphoma). 

Methotrexate Injection USP is indicated as a Disease Modifying Antirheumatic Drug (DMARD) in the following diseases where standard therapeutic interventions fail: 

  • Severe disabling psoriasis/psoriatic arthritis
  • Severe disabling rheumatoid arthritis (RA)
  • Severe disabling seronegative arthritides. 

In the treatment of psoriasis, Methotrexate Injection USP should be restricted to severe recalcitrant, disabling psoriasis, which is not adequately responsive to other forms of therapy, but only when the diagnosis has been established after dermatologic consultation. 

1.1 Pediatrics

Pediatrics (< 18 years of age): Safety and effectiveness in pediatric patients have not been established, other than in cancer chemotherapy. Therefore, Methotrexate Injection USP should not be used as a DMARD in pediatric patients. 

1.2 Geriatrics

Experience suggests that use in the geriatric population is associated with differences in safety, see 4.2 Recommended Dose and Dose Adjustment and 7.1.4 Warnings and Precautions, Geriatrics.

)

Find METHOTREXATE, VIALS medical information:

Find METHOTREXATE, VIALS medical information:

Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.

METHOTREXATE, VIALS Quick Finder

Product Monograph
Download Product Monograph

Health Professional Information

1 Indications

Methotrexate Injection USP is indicated for Neoplastic diseases: 

  • Choriocarcinoma: Methotrexate - as single chemotherapy or in combination with other drugs.
  • Intermediate, or high-grade Non-Hodgkin's Lymphoma - as part of ProMACE-CytaBOM, ProMACE-MOPP, and Magrath protocols.
  • Breast Cancer - as part of CMF (cyclophosphamide-methotrexate-fluorouracil) therapy.
  • Acute Lymphoblastic Leukemia - as maintenance therapy.
  • Head and Neck Cancer - in combination with other chemotherapies.
  • Gastric Cancer - palliative combination chemotherapy.
  • Metastasis of unknown primary - as palliative combination chemotherapy.
  • Osteogenic sarcoma (adjuvant) - high dose methotrexate with leucovorin rescue (HDMTX-LV)
  • Bladder Cancer (advanced) - as part of the M-VAC Regimen.
  • Leptomeningeal spread of malignancies (carcinomatosis/leukemia/lymphoma) as a single chemotherapy or alternating with Ara-C
  • Burkitt's lymphoma.
  • Advanced stages of childhood lymphoma (III and IV, St. Jude's Childrens' Research Hospital Staging System).
  • Advanced cases of mycosis fungoides (cutaneous T-cell lymphoma). 

Methotrexate Injection USP is indicated as a Disease Modifying Antirheumatic Drug (DMARD) in the following diseases where standard therapeutic interventions fail: 

  • Severe disabling psoriasis/psoriatic arthritis
  • Severe disabling rheumatoid arthritis (RA)
  • Severe disabling seronegative arthritides. 

In the treatment of psoriasis, Methotrexate Injection USP should be restricted to severe recalcitrant, disabling psoriasis, which is not adequately responsive to other forms of therapy, but only when the diagnosis has been established after dermatologic consultation. 

1.1 Pediatrics

Pediatrics (< 18 years of age): Safety and effectiveness in pediatric patients have not been established, other than in cancer chemotherapy. Therefore, Methotrexate Injection USP should not be used as a DMARD in pediatric patients. 

1.2 Geriatrics

Experience suggests that use in the geriatric population is associated with differences in safety, see 4.2 Recommended Dose and Dose Adjustment and 7.1.4 Warnings and Precautions, Geriatrics.

Resources

Didn’t find what you were looking for? 

Contact us

Call 1-800-463-6001*

*Contact Medical Information. 9AM-5PM ET Monday to Friday; excluding holidays.

Medical Inquiry

Submit a medical question for Pfizer prescription products.

Report Adverse Event

Pfizer Safety

Contact Pfizer Safety to report an adverse event, side effect or concern about the quality of a Pfizer product: 1 866 723-7111.

To report an adverse event related to COMIRNATY, and you are not part of a clinical trial* for this product, click the link below to submit your information:

Pfizer Safety Reporting Site

*If you are involved in a clinical trial for this product, adverse events should be reported to your coordinating study site.

Canada Vigilance Program 

You may also contact the Canada Vigilance Program directly to report adverse events or product quality concerns at 1-866-234-2345 or www.healthcanada.gc.ca/medeffect.